CXCR4 is a good survival prognostic indicator in multiple myeloma patients

Leukemia Research

Volumn 37, Issue 9, 2013, Pages 1083-1088

  Bao, Li ^a   Lai, Yueyun ^a   Liu, Yanrong ^a   Qin, Yazhen ^a   Zhao, Xiaosu ^a   Lu, Xijing ^a   Jiang, Qian ^a   Lu, Jin ^a   Huang, Xiaojun ^a  

^a PEKING UNIVERSITY PEOPLE S HOSPITAL   (China)

Author keywords

Bone marrow cells; CXCR4; Multiple myeloma; SDF 1 ; Survival

Indexed keywords

ALKALINE PHOSPHATASE; BETA 2 MICROGLOBULIN; BORTEZOMIB; CD56 ANTIGEN; CD9 ANTIGEN; CHEMOKINE RECEPTOR CXCR4; CREATININE; HEMOGLOBIN; STEM CELL FACTOR RECEPTOR; STROMAL CELL DERIVED FACTOR 1ALPHA; THALIDOMIDE;

ADULT; AGED; ALKALINE PHOSPHATASE BLOOD LEVEL; ARTICLE; BONE DESTRUCTION; CANCER PROGNOSIS; CANCER STAGING; CANCER SURVIVAL; CHROMOSOME ABERRATION; CHROMOSOME ANALYSIS; CHROMOSOME DELETION; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DISEASE ACTIVITY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; FLOW CYTOMETRY; HEMOGLOBIN BLOOD LEVEL; HUMAN; HYPERCALCEMIA; MAJOR CLINICAL STUDY; MALE; MULTIPLE MYELOMA; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PRIORITY JOURNAL; PROSPECTIVE STUDY; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; PROTEIN FUNCTION; SURVIVAL PREDICTION; SURVIVAL TIME;

BONE MARROW CELLS; CXCR4; MULTIPLE MYELOMA; SDF-1Α; SURVIVAL;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BORONIC ACIDS; CHEMOKINE CXCL12; CHROMOSOME ABERRATIONS; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; FLOW CYTOMETRY; FOLLOW-UP STUDIES; HUMANS; IN SITU HYBRIDIZATION, FLUORESCENCE; MALE; MIDDLE AGED; MULTIPLE MYELOMA; NEOPLASM STAGING; PROGNOSIS; PROSPECTIVE STUDIES; PYRAZINES; RECEPTORS, CXCR4; SURVIVAL RATE; THALIDOMIDE; TUMOR MARKERS, BIOLOGICAL;

EID: 84880934158     PISSN: 01452126     EISSN: 18735835     Source Type: Journal    
DOI: 10.1016/j.leukres.2013.06.002     Document Type: Article

References (39)

1. Kyle R.A., Rajkumar S.V. Multiple myeloma. N Engl J Med 2004, 351:1860-1873.
2. Alsayed Y., Ngo H., Runnels J., Leleu X., Singha U.K., Pitsillides C.M., et al. Mechanisms of regulation of CXCR4/SDF-1 (CXCL12)-dependent migration and homing in multiple myeloma. Blood 2007, 109:2708-2717.
3. Hideshima T., Chauhan D., Hayashi T., Podar K., Akiyama M., Gupta D., et al. The biological sequelae of stromal cell-derived factor-1alpha in multiple myeloma. Mol Cancer Ther 2002, 1:539-544.
4. Trentin L., Miorin M., Facco M., Baesso I., Carraro S., Cabrelle A., et al. Multiple myeloma plasma cells show different chemokine receptor profiles at sites of disease activity. Br J Haematol 2007, 138:594-602.
5. Vacca A., Scavelli C., Montefusco V., Di Pietro G., Neri A., Mattioli M., et al. Thalidomide downregulates angiogenic genes in bone marrow endothelial cells of patients with active multiple myeloma. J Clin Oncol 2005, 23:5334-5346.
6. Oliveira A.M., Maria D.A., Metzger M., Linardi C., Giorgi R.R., Moura F., et al. Thalidomide treatment down-regulates SDF-1alpha and CXCR4 expression in multiple myeloma patients. Leuk Res 2009, 33:970-973.
7. Mahindra A., Laubach J., Raje N., Munshi N., Richardson P.G., Anderson K. Latest advances and current challenges in the treatment of multiple myeloma. Nat Rev Clin Oncol 2012, 9:135-143.
8. Niesvizky R., Mark T.M., Ward M., Jayabalan D.S., Pearse R.N., Manco M., et al. Overcoming the response plateau in multiple myeloma: a novel bortezomib-based strategy for secondary induction and high-yield CD34+ stem cell mobilization. Clin Cancer Res 2013, 19:1534-1546.
9. Criteria for the classification of monoclonal gammopathies, multiple myeloma and related disorders: a report of the International Myeloma Working Group. Br J Haematol 2003;121:749-57.
10. Durie B.G., Salmon S.E. A clinical staging system for multiple myeloma. Correlation of measured myeloma cell mass with presenting clinical features, response to treatment, and survival. Cancer 1975, 36:842-854.
11. Ooi L.L., Dunstan C.R. CXCL12/CXCR4 axis in tissue targeting and bone destruction in cancer and multiple myeloma. J Bone Miner Res 2009, 24:1147-1149.
12. Drach J., Gattringer C., Huber H. Expression of the neural cell adhesion molecule (CD56) by human myeloma cells. Clin Exp Immunol 1991, 83:418-422.
13. Leo R., Boeker M., Peest D., Hein R., Bartl R., Gessner J.E., et al. Multiparameter analyses of normal and malignant human plasma cells: CD38++, CD56+, CD54+, cIg+ is the common phenotype of myeloma cells. Ann Hematol 1992, 64:132-139.
14. Kraj M., Sokolowska U., Kopec-Szlezak J., Poglod R., Kruk B., Wozniak J., et al. Clinicopathological correlates of plasma cell CD56 (NCAM) expression in multiple myeloma. Leuk Lymphoma 2008, 49:298-305.
15. Sahara N., Takeshita A., Shigeno K., Fujisawa S., Takeshita K., Naito K., et al. Clinicopathological and prognostic characteristics of CD56-negative multiple myeloma. Br J Haematol 2002, 117:882-885.
16. Hundemer M., Klein U., Hose D., Raab M.S., Cremer F.W., Jauch A., et al. Lack of CD56 expression on myeloma cells is not a marker for poor prognosis in patients treated by high-dose chemotherapy and is associated with translocation t(11;14). Bone Marrow Transplant 2007, 40:1033-1037.
17. De Bruyne E., Bos T.J., Asosingh K., Vande Broek I., Menu E., Van Valckenborgh E., et al. Epigenetic silencing of the tetraspanin CD9 during disease progression in multiple myeloma cells and correlation with survival. Clin Cancer Res 2008, 14:2918-2926.
18. Miettinen M., Lasota J. KIT (CD117): a review on expression in normal and neoplastic tissues, and mutations and their clinicopathologic correlation. Appl Immunohistochem Mol Morphol 2005, 13:205-220.
19. Ocqueteau M., Orfao A., Garcia-Sanz R., Almeida J., Gonzalez M., San Miguel J.F. Expression of the CD117 antigen (c-Kit) on normal and myelomatous plasma cells. Br J Haematol 1996, 95:489-493.
20. Bataille R., Pellat-Deceunynck C., Robillard N., Avet-Loiseau H., Harousseau J.L., Moreau P. CD117 (c-kit) is aberrantly expressed in a subset of MGUS and multiple myeloma with unexpectedly good prognosis. Leuk Res 2008, 32:379-382.
21. Vande Broek I., Leleu X., Schots R., Facon T., Vanderkerken K., Van Camp B., et al. Clinical significance of chemokine receptor (CCR1, CCR2 and CXCR4) expression in human myeloma cells: the association with disease activity and survival. Haematologica 2006, 91:200-206.
22. Hanamura I., Stewart J.P., Huang Y., Zhan F., Santra M., Sawyer J.R., et al. Frequent gain of chromosome band 1q21 in plasma-cell dyscrasias detected by fluorescence in situ hybridization: incidence increases from MGUS to relapsed myeloma and is related to prognosis and disease progression following tandem stem-cell transplantation. Blood 2006, 108:1724-1732.
23. Wu K.L., Beverloo B., Lokhorst H.M., Segeren C.M., van der Holt B., Steijaert M.M., et al. Abnormalities of chromosome 1p/q are highly associated with chromosome 13/13q deletions and are an adverse prognostic factor for the outcome of high-dose chemotherapy in patients with multiple myeloma. Br J Haematol 2007, 136:615-623.
24. Chang H., Qi X., Trieu Y., Xu W., Reader J.C., Ning Y., et al. Multiple myeloma patients with CKS1B gene amplification have a shorter progression-free survival post-autologous stem cell transplantation. Br J Haematol 2006, 135:486-491.
25. Chang H., Trieu Y., Qi X., Jiang N.N., Xu W., Reece D. Impact of cytogenetics in patients with relapsed or refractory multiple myeloma treated with bortezomib: adverse effect of 1q21 gains. Leuk Res 2011, 35:95-98.
26. Chang H., Yeung J., Xu W., Ning Y., Patterson B. Significant increase of CKS1B amplification from monoclonal gammopathy of undetermined significance to multiple myeloma and plasma cell leukaemia as demonstrated by interphase fluorescence in situ hybridisation. Br J Haematol 2006, 134:613-615.
27. Al-Sahmani M., Trnavska I., Sevcikova S., Antosova M., Antosova L., Kissova J., et al. Prognostic significance of morphological assessment of plasma cells in multiple myeloma. Neoplasma 2011, 58:554-560.
28. Xiong W., Wu X., Starnes S., Johnson S.K., Haessler J., Wang S., et al. An analysis of the clinical and biologic significance of TP53 loss and the identification of potential novel transcriptional targets of TP53 in multiple myeloma. Blood 2008, 112:4235-4246.
29. He J., Yang L., Meng X., Wei G., Wu W., Han X., et al. A Retrospective analysis of cytogenetic and clinical characteristics in patients with multiple myeloma. Am J Med Sci 2013, 345:88-93.
30. Lai Y.Y., Huang X.J., Cai Z., Cao X.S., Chen F.P., Chen X.Q., et al. Prognostic power of abnormal cytogenetics for multiple myeloma: a multicenter study in China. Chin Med J (Engl) 2012, 125:2663-2670.
31. Avet-Loiseau H., Attal M., Moreau P., Charbonnel C., Garban F., Hulin C., et al. Genetic abnormalities and survival in multiple myeloma: the experience of the Intergroupe Francophone du Myelome. Blood 2007, 109:3489-3495.
32. Gutierrez N.C., Castellanos M.V., Martin M.L., Mateos M.V., Hernandez J.M., Fernandez M., et al. Prognostic and biological implications of genetic abnormalities in multiple myeloma undergoing autologous stem cell transplantation: t(4;14) is the most relevant adverse prognostic factor, whereas RB deletion as a unique abnormality is not associated with adverse prognosis. Leukemia 2007, 21:143-150.
33. Dewald G.W., Therneau T., Larson D., Lee Y.K., Fink S., Smoley S., et al. Relationship of patient survival and chromosome anomalies detected in metaphase and/or interphase cells at diagnosis of myeloma. Blood 2005, 106:3553-3558.
34. Stewart A.K., Fonseca R. Prognostic and therapeutic significance of myeloma genetics and gene expression profiling. J Clin Oncol 2005, 23:6339-6344.
35. San-Miguel J.F., Richardson P.G., Sonneveld P., Schuster M.W., Irwin D., Stadtmauer E.A., et al. Efficacy and safety of bortezomib in patients with renal impairment: results from the APEX phase 3 study. Leukemia 2008, 22:842-849.
36. Richardson P.G., Sonneveld P., Schuster M., Irwin D., Stadtmauer E., Facon T., et al. Extended follow-up of a phase 3 trial in relapsed multiple myeloma: final time-to-event results of the APEX trial. Blood 2007, 110:3557-3560.
37. Harousseau J.L., Palumbo A., Richardson P.G., Schlag R., Dimopoulos M.A., Shpilberg O., et al. Superior outcomes associated with complete response in newly diagnosed multiple myeloma patients treated with nonintensive therapy: analysis of the phase 3 VISTA study of bortezomib plus melphalan-prednisone versus melphalan-prednisone. Blood 2010, 116:3743-3750.
38. Codony-Servat J., Tapia M.A., Bosch M., Oliva C., Domingo-Domenech J., Mellado B., et al. Differential cellular and molecular effects of bortezomib, a proteasome inhibitor, in human breast cancer cells. Mol Cancer Ther 2006, 5:665-675.
39. Madden S.L., Cook B.P., Nacht M., Weber W.D., Callahan M.R., Jiang Y., et al. Vascular gene expression in nonneoplastic and malignant brain. Am J Pathol 2004, 165:601-608.